Skip to Content

Results of OlympiA are practice changing in treatment of breast cancer

Adjuvant olaparib treatment significantly improves invasive disease-free survival in women with BRCA mutation and high-risk HER2-negative breast cancer. With a median follow-up of 2.5 years, olaparib-treated patients had a 42% reduction in the risk of developing invasive relapse compared to placebo.

Self Diagnosis Of Early Breast Cancer

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top